Retatrutide Shows 24.2% Weight Reduction in Phase II Trial

Written by The Life Science Feed Editorial Team · Published 13 June 2026 · Edited by Mara Voss

> Obesity and its associated cardiometabolic comorbidities present a significant clinical challenge, often requiring multifaceted interventions beyond lifestyle modifications. The emergence of novel incretin-based therapies offers new avenues for management. A recent Phase II trial of retatrutide, a triple agonist, has shown a mean weight reduction of 24.2%, indicating a potent therapeutic effect.

KEY TAKEAWAYS

- The Pivot: Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, demonstrated greater weight loss than previously reported dual agonists.
- The Data: Participants receiving the highest dose of retatrutide achieved a mean weight reduction of 24.2% from baseline at 48 weeks.
- The Action: While not yet approved, these data suggest retatrutide may offer a highly effective pharmacological option for weight management, warranting close attention to ongoing Phase III trials.

The management of obesity is complex, with a significant proportion of patients failing to achieve sustainable weight loss through diet and exercise alone. Pharmacological interventions have evolved, with glucagon-like peptide-1 (GLP-1) receptor agonists demonstrating efficacy in weight reduction and improvement in metabolic parameters. Newer agents, such as dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have further enhanced these effects. Retatrutide represents a novel investigational therapy, designed as a triple agonist for the GIP, GLP-1, and glucagon receptors, aiming to leverage the synergistic effects of these pathways for enhanced metabolic benefits.1 Obesity is a chronic, relapsing disease with a global prevalence that has nearly tripled since 1975. It is a major risk factor for numerous non-communicable diseases, including cardiovascular disease, type 2 diabetes, certain cancers, and musculoskeletal disorders, significantly impacting quality of life and healthcare systems. The development of more effective and sustained weight loss therapies is crucial to address this public health challenge. Current pharmacological options, while effective, often do not achieve the magnitude of weight loss seen with bariatric surgery, highlighting the need for agents with greater efficacy. Retatrutide's triple-agonist mechanism targets multiple pathways involved in appetite regulation, energy expenditure, and glucose homeostasis, offering a potentially more comprehensive approach to weight management.

The Trial Design and Key Findings

A Phase II, randomised, double-blind, placebo-controlled trial evaluated the efficacy and safety of retatrutide in adults with obesity or overweight with at least one weight-related comorbidity, excluding type 2 diabetes.1 The trial enrolled

338 participants, who were randomly assigned to receive either placebo or one of several doses of retatrutide (1 mg, 4 mg, 8 mg, or 12 mg) administered subcutaneously once weekly for 48 weeks.1

Participants included in the study had a body mass index (BMI) of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. The exclusion of individuals with type 2 diabetes aimed to isolate the effects of retatrutide on weight loss and metabolic parameters in a population primarily affected by obesity without the confounding factors of established diabetes management. The randomisation process ensured an even distribution of baseline characteristics across treatment arms, enhancing the internal validity of the study findings.

The primary endpoint was the percentage change in body weight from baseline to week 24. Secondary endpoints included the percentage change in body weight from baseline to week 48, the proportion of participants achieving specific weight loss thresholds (e.g., ≥5%, ≥10%, ≥15%), and changes in cardiometabolic risk factors.1

At week 24, participants receiving retatrutide showed dose-dependent reductions in body weight. The mean percentage change in body weight from baseline was -8.7% with 1 mg, -17.1% with 4 mg, -17.5% with 8 mg, and -14.6% with 12 mg, compared to -2.0% with placebo ($p<0.001$ for all active doses versus placebo).1

By week 48, the weight loss continued to increase. The mean percentage change in body weight from baseline was -8.7% with 1 mg, -21.2% with 4 mg, -22.8% with 8 mg, and -24.2% with 12 mg, compared to -2.1% with placebo ($p<0.001$ for all active doses versus placebo).1 Notably, 100% of participants in the 8 mg and 12 mg retatrutide groups achieved at least 5% weight loss, compared to 27% in the placebo group.1 Furthermore, 83% of participants in the 12 mg group achieved at least 20% weight loss, a threshold often associated with significant health benefits.1

Beyond weight reduction, retatrutide also demonstrated improvements in several cardiometabolic parameters. Significant reductions were observed in fasting glucose, insulin, HbA1c, lipid levels (total cholesterol, LDL-C, triglycerides), and blood pressure in the retatrutide groups compared to placebo.1 Liver fat content, assessed by magnetic resonance imaging, also showed substantial reductions, with a mean decrease of 81.8% in the 12 mg group, suggesting potential benefits for non-alcoholic fatty liver disease.1

The safety profile was consistent with other incretin-based therapies. The most common adverse events were gastrointestinal, including nausea, diarrhoea, vomiting, and constipation, generally mild to moderate in severity and transient.1 Discontinuation rates due to adverse events were 16% in the 12 mg group and lower in other active treatment groups, compared to 5% in the placebo group.1

While these Phase II results are compelling, the trial duration of 48 weeks limits the assessment of long-term efficacy and safety. The relatively small sample size for each dose group also warrants caution, and larger Phase III trials are necessary to confirm these findings across broader and more diverse patient populations. The exclusion of individuals with type 2 diabetes means the full spectrum of metabolic benefits and risks in this specific cohort remains to be fully elucidated. Further research is also needed to understand the precise mechanisms contributing to the observed triple-agonist effects and their differential impact compared to dual agonists.

CLINICAL IMPLICATIONS

The data from the retatrutide Phase II trial present a significant development in the pharmacological management of obesity. A mean weight reduction of 24.2% at 48 weeks with the highest dose is a substantial

outcome, surpassing the efficacy observed with current GLP-1 receptor agonists and even dual GLP-1/GIP agonists like tirzepatide. For clinicians, this suggests a future where greater weight loss targets may be achievable for patients, potentially leading to more profound improvements in obesity-related comorbidities such as dyslipidaemia, hypertension, and non-alcoholic fatty liver disease. The observed reductions in liver fat content are particularly noteworthy, given the increasing prevalence of NAFLD and the limited therapeutic options available.

The industry implications are clear: the race for the most effective anti-obesity medicine continues to intensify. Eli Lilly, with both tirzepatide and now retatrutide in its pipeline, appears poised to dominate this therapeutic area. The triple-agonist mechanism of retatrutide, targeting GIP, GLP-1, and glucagon receptors, offers a glimpse into the next generation of incretin mimetics. While the gastrointestinal side effects are consistent with the class, their management will remain a key aspect of patient adherence and tolerability. The challenge for prescribers will be to navigate an increasingly crowded market, understanding the nuanced differences in efficacy and safety profiles between these potent agents.

For patients, the prospect of achieving such significant weight loss without bariatric surgery is transformative. A 20% or greater weight reduction can dramatically improve quality of life, reduce the burden of chronic disease, and potentially extend lifespan. However, access and cost will be critical considerations. As these highly effective therapies become available, healthcare systems and payers will need to address how to ensure equitable access for the millions of individuals living with obesity, moving beyond the current paradigm where these medicines are often considered elective or luxury treatments. The long-term sustainability of these effects and the potential for weight regain upon discontinuation will also be important factors for patient counselling and treatment planning.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Jastreboff AM, Kaplan LM, Frías AJ, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301992

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com